Evidence map›Paper›PMID 21544002›Full record

ArticleMedical care2011

Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.

Becky A Briesacher, Yanfang Zhao, Jeanne M Madden, Fang Zhang, Alyce S Adams, Jennifer Tjia, Dennis Ross-Degnan, Jerry H Gurwitz, Stephen B Soumerai

Abstract readComparative Study
In one paragraph

Article in Medical care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. How Did Medicare Part D Affect Racial and Ethnic Disparities in Drug Coverage?The journals of gerontology. Series B, Psychological sciences and social sciences · 2016
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Becky A BriesacherDivision of Geriatric Medicine and Meyers Primary Care Institute, University of Massachusetts Medical School and Meyers Primary Care, Worcester, Boston, MA, USA. Becky.Briesacher@umassmed.edu
Yanfang Zhao
Jeanne M Madden
Fang Zhang
Alyce S Adams
Jennifer Tjia
Dennis Ross-Degnan
Jerry H Gurwitz
Stephen B Soumerai

Funding

Impact of Medicare Drug Benefit on Use and Cost-related Underuse of MedicinesR01AG028745 · NIA · HARVARD PILGRIM HEALTH CARE, INC. · PI SOUMERAI, STEPHEN B · 2006 to 2014
$3.2M
Cost-related Underuse of Medications and the Health of Older AdultsK01AG031836 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BRIESACHER, BECKY A · 2008 to 2012
$679k
NIA NIH HHS K01 AG031836NIA NIH HHS R01 AG028745
6 · The paper itself

Abstract

contextThe full effect of Medicare Part D, after the initial policy transition period and across the United States Medicare population, remains unclear.

objectiveTo estimate nationally representative changes in prescription drug use and out-of-pocket drug costs 2 years after implementation of Part D. DESIGN, SETTING, AND

participantsWe examined study outcomes over 8 years (2000 to 2007) and estimated changes after Part D, accounting for earlier trends. Our analyses used the community-dwelling sample of the Medicare Current Beneficiary Survey (unweighted unique n=38,798). Actual post-Part D outcomes were compared with projected values using 2000 to 2005 data. Subgroup analyses and standardization weights were used to address population-level shifts over time in health status and demographic characteristics.

main outcome measuresAnnual prescription drug fills and out-of-pocket drug costs.

resultsWe observed significant average per person increases of 1.8 prescription fills [95% confidence interval (CI), 1.1-2.5] in 2006 and 3.4 prescription fills (95% CI, 2.7-4.1) in 2007 above pre-Part D increases of 0.9 prescription fills per year. Average out-of-pocket drug costs decreased significantly by $143 (95% CI, -182.5--103.1) in 2006 and $148 (95% CI, -181.2--114.1) in 2007 above average pre-Part D increases of $12 per year. Prescription fills did not change for beneficiaries with fair to poor health until 2007 when large increases occurred (increases of 3.7 to 11.0 fills above pre-Part D trends). Significant reductions in OOP drug costs occurred in 2006 and persisted into 2007 across all groups except for sick and poor beneficiaries without Medicaid.

conclusionsAfter the transition year of 2006, the impact of Part D seemed larger and more consistent across the Medicare population. Of note, sick and poor beneficiaries experienced significant improvements in prescription drug use in 2007.

Indexed as

Drug Utilization ReviewFees, PharmaceuticalFinancing, PersonalOutcome Assessment, Health CareAgedAged, 80 and overFemaleHealth StatusHumansInsurance CoverageLongitudinal StudiesMaleMedicare Part DMiddle AgedUnited States

Identifiers

PMID21544002
PMCPMC3151472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.